Published case reports and clinical literature documenting psychosis, suicidality, psychiatric hospitalization, behavioral dysregulation, dependence, and withdrawal associated with kratom use.
A 35‑year‑old with schizoaffective disorder developed new‑onset paranoid delusions after escalating kratom use. No prior psychotic delusions in seven previous hospitalizations. Kratom's stimulant properties likely induced psychosis.
Read Case →A 43‑year‑old man with PTSD took an entire bottle of liquid kratom and developed auditory/visual hallucinations, delusions of grandeur, and insomnia for 7 days. Required hospitalization. Kratom alone induced a manic psychosis.
Read Case →32‑year‑old developed severe cholestatic liver injury after kratom use; authors conclude kratom has "potentially lethal side effects" and contributes to psychiatric and medical harm.
Read Report →A 31‑year‑old man under the influence of kratom, cannabinoids, and 7‑OH amputated both auricles and his penis. Required emergency surgery, psychiatric care, and later reconstructive surgery. Extreme substance‑induced self‑harm.
Read Case →A 38‑year‑old woman with opioid use disorder escalated to 35‑42 g/day kratom. Developed tolerance, withdrawal, and lost $75/week. Overdosed on psychiatric medications in a suicide attempt. Kratom directly contributed to a life‑threatening suicide attempt.
Read Case →15‑year‑old ingested 45 capsules (22.5g) as suicide attempt. Tachycardia, miosis, tremors, hypokalemia, elevated QTc (474 ms). Required psychiatric hospitalization.
Read Case →A 37‑year‑old woman developed severe opioid‑like withdrawal after 2 years of kratom extract use, requiring high‑dose clonidine (2 mg over 36 hours) and hydroxyzine. Lost significant weight, hid use from family. Classic addiction and withdrawal.
Read Report →Naltrexone triggered severe opioid‑like withdrawal in a daily kratom user, requiring ICU and high‑dose benzodiazepines. Demonstrates physical dependence akin to classic opioids.
Read Case →Chronic kratom user developed withdrawal (COWS 9); required buprenorphine for symptom control. Opioid‑type dependence and withdrawal meeting DSM‑5 criteria.
Read Report →A 44‑year‑old man developed severe anxiety, dysphoria, and insomnia during kratom withdrawal that persisted for months. Responded to clomipramine after multiple antidepressants failed.
Read Report →A 55‑year‑old woman developed severe withdrawal (hallucinations, fever, tachycardia, hypotension) after elective surgery, leading to ICU admission for aspiration pneumonia. Kratom dependence complicated routine medical care.
Read Case →32‑year‑old required hospitalization for severe liver injury and psychiatric evaluation after kratom use. Highlights need for psychiatric and medical comanagement.
Read Report →This case represents one of the most extreme forms of substance‑induced self‑harm, showing that kratom can precipitate psychotic episodes leading to catastrophic mutilation.
Read Case →Patient became hostile, verbally abusive, accused family members of theft, and resigned from job – severe behavioral dysregulation requiring psychiatric admission.
Read Case →A man in his 40s with 12 years of kratom use escalated to 40 g/day. Successfully tapered off kratom over 6 months using buprenorphine/naloxone. Need for opioid‑agonist treatment proves opioid‑like addiction potential.
Read Case →Patient on ~90g kratom/day developed serotonin syndrome and QTc prolongation from drug interactions. Required buprenorphine to stop kratom. Demonstrates kratom's abuse liability and need for medication‑assisted treatment.
Read Report →Clomipramine successfully treated prolonged withdrawal‑associated anxiety and dysphoria after kratom cessation – highlights psychiatric complexity of kratom dependence.
Read Report →The psychiatric literature on kratom, though based primarily on case reports and case series, documents a recurring pattern of acute psychiatric decompensation, psychosis, suicidality, severe behavioral dysregulation, and opioid‑like dependence/withdrawal. These events have required psychiatric hospitalization, intensive care, and medication‑assisted treatment. While causality is confounded by polysubstance use and preexisting psychiatric conditions in many cases, the temporal relationship and symptom profiles suggest kratom can act as a behavioral‑health precipitant in vulnerable individuals. The emergence of severe self‑harm, paranoia, and withdrawal syndromes indicates that kratom is not a benign botanical but carries meaningful psychiatric and addiction risk.
